Zhejiang CONBA Pharmaceutical Co Ltd Capital Reinvestment Ratio
Zhejiang CONBA Pharmaceutical Co Ltd capital reinvestment ratio. Zhejiang CONBA Pharmaceutical Co Ltd (600572) has a Capital Reinvestment Ratio of 0.20x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥133.43 Million) in capital expenditures (CN¥26.90 Million). Check total reinvestment intensity of Zhejiang CONBA Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Zhejiang CONBA Pharmaceutical Co Ltd (2003–2025)
Capital reinvestment ratio of Zhejiang CONBA Pharmaceutical Co Ltd from 2003 to 2025. This chart tracks Zhejiang CONBA Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 23 annual periods. Also explore Zhejiang CONBA Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Zhejiang CONBA Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2003–2025)
Zhejiang CONBA Pharmaceutical Co Ltd capital reinvestment ratio by year from 2003 to 2025. For the full cash flow conversion analysis, see 600572 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | CN¥942.61 Million | CN¥147.26 Million | ▼ -45.6% |
| 2024 | 0.29x | CN¥1.01 Billion | CN¥290.63 Million | ▲ +23.3% |
| 2023 | 0.23x | CN¥898.64 Million | CN¥209.14 Million | ▼ -7.8% |
| 2022 | 0.25x | CN¥1.16 Billion | CN¥291.75 Million | ▼ -60.5% |
| 2021 | 0.64x | CN¥889.94 Million | CN¥568.37 Million | ▲ +73.4% |
| 2020 | 0.37x | CN¥1.25 Billion | CN¥460.40 Million | ▲ +26.9% |
| 2019 | 0.29x | CN¥925.50 Million | CN¥268.79 Million | ▼ -58.2% |
| 2018 | 0.70x | CN¥545.78 Million | CN¥379.63 Million | ▲ +69.8% |
| 2017 | 0.41x | CN¥712.27 Million | CN¥291.80 Million | ▲ +71.4% |
| 2016 | 0.24x | CN¥969.71 Million | CN¥231.83 Million | ▼ -30.8% |
| 2015 | 0.35x | CN¥831.26 Million | CN¥286.97 Million | ▼ -50.3% |
| 2014 | 0.70x | CN¥617.43 Million | CN¥429.23 Million | ▼ -65.7% |
| 2013 | 2.02x | CN¥235.36 Million | CN¥476.32 Million | ▲ +107.4% |
| 2012 | 0.98x | CN¥245.76 Million | CN¥239.76 Million | ▲ +38.1% |
| 2011 | 0.71x | CN¥188.36 Million | CN¥133.09 Million | ▼ -21.3% |
| 2010 | 0.90x | CN¥125.93 Million | CN¥113.07 Million | ▲ +158.3% |
| 2009 | 0.35x | CN¥153.39 Million | CN¥53.32 Million | ▼ -57.8% |
| 2008 | 0.82x | CN¥98.56 Million | CN¥81.12 Million | ▼ -19.5% |
| 2007 | 1.02x | CN¥79.98 Million | CN¥81.83 Million | ▲ +10.9% |
| 2006 | 0.92x | CN¥71.20 Million | CN¥65.67 Million | ▼ -6.9% |
| 2005 | 0.99x | CN¥117.65 Million | CN¥116.57 Million | ▲ +1.7% |
| 2004 | 0.97x | CN¥65.47 Million | CN¥63.81 Million | ▲ +61.0% |
| 2003 | 0.61x | CN¥66.64 Million | CN¥40.34 Million | — |